Alternative Liquidity Index Offers To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash

8/29/23 3:17:25 AM ET

Major Pharmaceuticals

Health Care

Get the next $SVA alert in real time by email

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company's outstanding shares, for $0.03 per share in cash.

Get the next $SVA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SVA

Date	Price Target	Rating	Analyst

More analyst ratings

$SVA
Press Releases

Fastest customizable press release news feed in the world

Sinovac Amends Shareholder Rights Plan
Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, pol
2/21/24 2:56:00 AM ET
$SVA
Major Pharmaceuticals
Health Care
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
Board of Directors Unanimously Recommends Sinovac Shareholders NOT Tender Shares for purchase pursuant to the Offer to Purchase Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of Directors") unanimously determined that the partial tender offer (the "Tender Offer") by Alternative Liquidity Index LP ("Alternative Liquidity") to acquire up to 10,000,000 common shares of Sinovac (the "Shares") for $0.03 per share in cash (the "Offer Price") is NOT advisable and is NOT in the best interests of the Company or its shareholders ("Shareholders"). Accordingly, the Board
1/18/24 7:00:00 AM ET
$SVA
Major Pharmaceuticals
Health Care
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
Clinical trials will advance treatment of COVID-19 infection. Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection ("SA55 Injection") in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently. SINOVAC's SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24, 2023. The phase I clinical trial has confirmed its preliminar
9/11/23 5:55:00 AM ET
$SVA
Major Pharmaceuticals
Health Care

SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021. The Company also reported its unaudited financial for the second half and full year ended December 31, 2021. Second Half and Full Year 2021 Financial Summary Sales for the six months ended December 31, 2021 were $8.4 billion, compared to $442.9 million in the prior year period. Sales in 2021 were $19.4 billion, compared to $510.6 million in the prior year. The Company posted $3.4 billion of net income attributable to common sharehol
4/29/22 6:30:00 PM ET
$SVA
Major Pharmaceuticals
Health Care
SINOVAC Reports Unaudited First Half of 2021 Financial Results
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2021. First Half of 2021 Financial Summary Sales for the six months ended June 30, 2021 were $11.0 billion, compared to $67.7 million in the prior year period. The Company posted $5.1 billion of net income attributable to common shareholders, or $51.42 per basic and $44.80 per diluted share, in the six months ended June 30, 2021, compared to net loss attributable to common shareholders of $12.6 million, or $0.13 loss per basic and diluted share, in the prior year period. Mr. Weidon
12/30/21 4:05:00 PM ET
$SVA
Major Pharmaceuticals
Health Care
Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2020. The Company also reported its unaudited financial results for the fourth quarter ended December 31, 2020. Fourth Quarter and Full Year 2020 Financial Summary Sales for the fourth quarter of 2020 were $327.5 million, an increase from $81.1 million in the prior year period. Sales in 2020 were $510.6 million, an increase from $246.1 million in the prior year. Operating income for the fourth quarter increased by 583.7% from the prior
4/22/21 6:51:00 PM ET
$SVA
Major Pharmaceuticals
Health Care

SINOVAC Updates on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection ("SA55 Injection") in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently. SINOVAC's SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24, 2023. The phase I clinical trial has confirmed its preliminary safety profile in 40 healthy adults aged 18 to 65 in China. The
9/11/23 5:58:21 AM ET
$SVA
Major Pharmaceuticals
Health Care
Sinovac Biotech Board Unanimously Rejects an Unsolicited Partial Tender Offer from Alternative Liquidity Index To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of Directors") unanimously determined that the partial tender offer (the "Tender Offer") by Alternative Liquidity Index LP ("Alternative Liquidity") to acquire up to 10,000,000 common shares of Sinovac (the "Shares") for $0.03 per share in cash (the "Offer Price") is NOT advisable and is NOT in the best interests of the Company or its shareholders ("Shareholders"). Accordingly, the Board of Directors recommends that the Shareholders reject the Tender Offer and not tender their Shares for purchase pursuant to the Off
9/5/23 4:16:16 AM ET
$SVA
Major Pharmaceuticals
Health Care
Alternative Liquidity Index Offers To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company's outstanding shares, for $0.03 per share in cash.
8/29/23 3:17:25 AM ET
$SVA
Major Pharmaceuticals
Health Care

Alternative Liquidity Index Offers To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash

Chat with this insight

Recent Analyst Ratings for
$SVA

$SVA
SEC Filings

SEC Form 6-K filed by Sinovac Biotech, Ltd.

SEC Form 20-F filed by Sinovac Biotech, Ltd.

SEC Form 8-A12B/A filed by Sinovac Biotech, Ltd. (Amendment)

$SVA
Press Releases

Fastest customizable press release news feed in the world

Sinovac Amends Shareholder Rights Plan

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection

$SVA
Financials

Live finance-specific insights

$SVA
Market Insights

Live Market Insights

SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F

SINOVAC Reports Unaudited First Half of 2021 Financial Results

Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F

SINOVAC Updates on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection

Sinovac Biotech Board Unanimously Rejects an Unsolicited Partial Tender Offer from Alternative Liquidity Index To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash

Alternative Liquidity Index Offers To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash

$SVA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

SEC Form SC 13G/A filed by Sinovac Biotech, Ltd. (Amendment)

Alternative Liquidity Index Offers To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash

Chat with this insight

Recent Analyst Ratings for $SVA

$SVA SEC Filings

SEC Form 6-K filed by Sinovac Biotech, Ltd.

SEC Form 20-F filed by Sinovac Biotech, Ltd.

SEC Form 8-A12B/A filed by Sinovac Biotech, Ltd. (Amendment)

$SVA Press Releases

Fastest customizable press release news feed in the world

Sinovac Amends Shareholder Rights Plan

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection

$SVA Financials

Live finance-specific insights

$SVA Market Insights

Live Market Insights

SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F

SINOVAC Reports Unaudited First Half of 2021 Financial Results

Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F

SINOVAC Updates on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection

Sinovac Biotech Board Unanimously Rejects an Unsolicited Partial Tender Offer from Alternative Liquidity Index To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash

Alternative Liquidity Index Offers To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash

$SVA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

SEC Form SC 13G/A filed by Sinovac Biotech, Ltd. (Amendment)

Recent Analyst Ratings for
$SVA

$SVA
SEC Filings

$SVA
Press Releases

$SVA
Financials

$SVA
Market Insights

$SVA
Large Ownership Changes